The digital therapeutic solution halving hospitalization rates
Around 750,000 people live with chronic heart failure in Canada. The Medly program empowers patients with heart failure to manage their condition
Search
Implementing the generalized pustular psoriasis (GPP) Charter
Read more about the projects are implementing the generalized pustular psoriasis (GPP) Charter
Partnership with IBM to accelerate new antibody therapies
Boehringer Ingelheim collaborates with IBM to advance generative AI and foundation models for therapeutic antibody development
Stroke Risk Factors Symptoms
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. There is a simple test that can help everyone identify the most common symptoms of a stroke.
Streetvet: Free veterinary care
Learn more about StreetVet free veterinarian care for companion animals of the homeless
Closing healthcare gaps with continued vaccination campaigns
How we continue combating rabies through collaborative efforts and the use of drone delivery in rural Kenya.
Boehringer Ingelheim partners with PetMedix
Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
FRONTLINE becomes Brand of the Year 2019-2020
FRONTLINE becomes ‘Brand of the Year’ 2019-2020 in World Branding Awards
Tackling supply chain challenges for a country at war
We are there for our patients – even in crisis regions. A supply chain success story with our Ukrainian colleague Tetiana Nagirna from Kyiv.
ArisGlobal acquires Boehringer Ingelheim technology
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
Health equity for underserved communities
Introducing initiatives that improve access to healthcare for underserved communities
Are combination therapies the answer to battling KRAS cancers?
Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal
On two wheels for more animal health
Cowtribe’s social entrepreneurs win Boehringer Ingelheim's Accelerator Program.
Supporting Rabies Free Pakistan Indus Hospital
Rabies endangers thousands of human lives in Pakistan every year. We provide green collars and vaccines to improve situation.
Official partner to Cat Care for Life
Boehringer Ingelheim announces its new partnership with the CatCareforLife program.
Winners of 2020 BVDzero Case Awards
Winners of 2020 BVDzero Case Awards announced. 10 top clinical cases will receive a total prize of 15,000 euros.
Inauguration of new global center for veterinary vaccine R&D
Inauguration of a new global hi-tech centre for biological research and development in Lyon.
biopharmaceuticals-in-china
Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.
BIVF funding more than doubled to 250 M€
Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
cystic fibrosis phase II trial
The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
Aservo EquiHaler wins Red Dot 2020 for design quality
Aservo EquiHaler wins a prestigious Red Dot Award 2020 for outstanding design quality
New study paves the way for liver cirrhosis treatments
The ADVANCE study will be the most detailed observational study of its kind providing a detailed analysis of liver health.
Option to Acquire Trutino Biosciences
Option to Acquire Trutino Biosciences
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
Inauguration of new integrated Asian Veterinary R&D Center in China
Boehringer Ingelheim confirms its commitment to growth in China with the investment of 19 million euros in its new integrated Asian Veterinary Research & Development Center